Ken Griffin Mereo Biopharma Group PLC Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$3.45 - $4.87 $38,640 - $54,544	-11,200 Reduced 40.14%	16,700 $68,000
Q2 2024 Aug 14, 2024	SELL	$2.58 - $4.25 $13,158 - $21,675	-5,100 Reduced 15.45%	27,900 $100,000
Q1 2024 May 15, 2024	BUY	$2.3 - $4.05 $53,589 - $94,365	23,300 Added 240.21%	33,000 $108,000
Q4 2023 Feb 14, 2024	BUY	$1.19 - $2.42 $5,593 - $11,374	4,700 Added 94.0%	9,700 $22,000
Q3 2023 Nov 14, 2023	BUY	$1.15 - $1.67 $5,290 - $7,682	4,600 Added 1150.0%	5,000 $6,000
Q2 2023 Aug 14, 2023	SELL	$0.79 - $1.43 $474 - $858	-600 Reduced 60.0%	400 $0
Q1 2023 May 15, 2023	SELL	$0.71 - $1.22 $65,249 - $112,118	-91,900 Reduced 98.92%	1,000 $0
Q4 2022 Feb 14, 2023	SELL	$0.5 - $1.01 $3,350 - $6,767	-6,700 Reduced 6.73%	92,900 $69,000
Q3 2022 Nov 14, 2022	SELL	$0.82 - $1.73 $40,016 - $84,424	-48,800 Reduced 32.88%	99,600 $86,000

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $441M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.